Join the club for FREE to access the whole archive and other member benefits.

Bioage's lead therapies moved closer to the clinic


Key points from article :

BioAge after raising series c funding round, moved its lead therapies, BGE-117 and BGE-175, into phase 2 clinical trials.

BGE-175, will treat immune aging in older patients - initially those hospitalized with COVID-19.

“These additional funds... reverse or eradicate diseases and extend healthspan,” Kristen Fortney, CEO and co-founder, BioAge.

The new round brings the total amount of venture capital funding raised by BioAge to $127 million.

"Investors are showing more and more enthusiasm for aging as a space" - Fortney.

BioAge also announced the appointment of veteran biopharmaceutical drug developer Paul Rubin, as its chief medical officer.

Drugs are ready to begin phase 2 trials in indications that presently have no good therapeutic options.

“Our drugs can address age-related deficiencies in acute conditions, chronic diseases, resulting in healthy aging.” -Dr Rubin.

Lead therapies of BioAge to treat age related diseases enter phase 2 trials

Mentioned in this article:

Click on resource name for more details.


Developing a broad pipeline of therapies to extend human healthspan and lifespan

Kristen Fortney


Paul Rubin

Chief Medical Officer at Bioage Labs and Pharma and biotech Consultant at Rubin Pharma.